Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HB-48 in recurrent glioblastoma
CTR20253392Phase 2Active
- Sponsor
- Guchong Pharmaceutical
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HB-48 in glioblastoma (GBM), sponsored by Guchong Pharmaceutical. Primary endpoints: Safety and tolerability, Dose-limiting toxicity and dose selection and 1 more. Started Nov 2025; status: active.
02
Drugs
HB-48
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on CTR20253392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253392.